July 22, 2015 - Entera's drug for hypoparathyroidism, completed its first Phase II clinical trial. The trial met its safety and efficacy endpoint. The trial included 17 hypoparathyroidism patients and was carried out at the Lin Medical Center, Haifa as well as at the Hadassah Medical Center, Jerusalem. The study showed a significant reduction in calcium supplementation while maintaining the blood calcium levels. Entera’s oral PTH 1-34 was well tolerated and had a high level of compliance. No related adverse events were recorded in the 17 subjects completing the trial. (2 additional subjects were excluded from the trial following the first treatment day. One of these subjects had hypercalcemia prior to receiving the study drug and the other withdrew consent).